Case reports with durable therapeutic effects from the prospective phase 2 trial
Medicine: Case Reports and Study Protocols · 2020
DOI: 10.1097/md9.0000000000000010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicine: Case Reports and Study Protocols, 2020. Verfasst von Lu Xie und 6 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Rationale
For advanced osteosarcoma refractory to chemotherapy, our previous phase II trial of advanced osteosarcoma progressing after chemotherapy (Apatinib Plus camrelizumab for unresectable high-grade Osteosarcoma) revealed that although the combination of apatinib and camrelizumab seemed to prolong progression-free survival in comparison to single agent apatinib in treating advanced osteosarcoma, it did not reach the prespecified target of 6-month progression-free survival of 60% or greater. Until last follow-up, 2 durable therapeutic effects were observed. Here, we present these 2 cases with detailed clinical information to gain insights into the characteristics of these clinical beneficiaries. Patient concerns: We present the clinical courses of 2 cases. Case 1 was a 44-year-old male with the primary tumor located at proximal femur. Following routine chemotherapy for osteosarcoma, the patient developed multiple pulmonary metastases and local recurrence. Case 2 was a 14-year-old female with primary tumor located at proximal tibia and fibula. Her disease progressed during chemotherapy after definitive surgery with multiple calcified pulmonary metastases. Diagnosis: High grade osteosarcoma with progression upon routine chemotherapy Interventions: Both the patients were enrolled in the advanced osteosarcoma progressing after chemotherapy trial and were treated with Apatinib 500 mg orally once daily and Camrelizumab 200 mg intravenously administered once every 2 weeks in a 4-week (28 days) cycle. Outcomes: Case 1 showed a partial response for 2 years after enrollment. The dose of apatinib was reduced due to adverse events and eventually stopped. As of February 2020, the lung lesions show a stable response and the patient is disease-free. The residual femoral lesions are planned to be treated by radiation therapy. Case 2 showed stable disease for more than 18 months after the enrollment. She is the only patient from the trial who is still using the drug combination. The last follow-up time was March 1st of 2020. Lessons: These 2 cases suggested osteosarcoma might not always be refractory to anti-PD-1/ programmed death-ligand 1 axial therapy. More prospective trials are needed to determine the biomarkers that may aid in patient selection for this combination.
Trial registration
This trial is registered with ClinicalTrials.gov, number NCT03359018.
Zitieren
APA
Xie, L., Xu, J., Sun, X., Tang, X., Sun, K., Li, Y., & Guo, W. (2020). Case reports with durable therapeutic effects from the prospective phase 2 trial. Medicine: Case Reports and Study Protocols. https://doi.org/10.1097/md9.0000000000000010
Vancouver
Xie L, Xu J, Sun X, Tang X, Sun K, Li Y, et al. Case reports with durable therapeutic effects from the prospective phase 2 trial. Medicine: Case Reports and Study Protocols. 2020. doi:10.1097/md9.0000000000000010
BibTeX
@article{Xie2020,
author = {Xie, Lu and Xu, Jie and Sun, Xin and Tang, Xiaodong and Sun, Kunkun and Li, Yuan and Guo, Wei},
title = {Case reports with durable therapeutic effects from the prospective phase 2 trial},
journal = {Medicine: Case Reports and Study Protocols},
year = {2020},
doi = {10.1097/md9.0000000000000010}
}
EUVIMED